Patrick O’brien Sells 29,184 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) COO Patrick O’brien sold 29,184 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $578,426.88. Following the completion of the sale, the chief operating officer now directly owns 535,201 shares in the company, valued at $10,607,683.82. This trade represents a 5.17 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Arrowhead Pharmaceuticals Stock Up 0.9 %

Shares of ARWR stock traded up $0.17 during trading hours on Tuesday, hitting $19.67. 1,197,900 shares of the company were exchanged, compared to its average volume of 1,241,250. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -3.92 and a beta of 0.97. Arrowhead Pharmaceuticals, Inc. has a one year low of $17.05 and a one year high of $39.83. The business’s 50-day simple moving average is $21.03 and its two-hundred day simple moving average is $22.56. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 3.9% during the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after purchasing an additional 333,333 shares during the period. State Street Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock valued at $123,083,000 after buying an additional 516,569 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after buying an additional 26,171 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Arrowhead Pharmaceuticals by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock worth $19,504,000 after acquiring an additional 12,574 shares during the period. Finally, Millennium Management LLC grew its position in Arrowhead Pharmaceuticals by 61.9% in the 2nd quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock valued at $13,755,000 after buying an additional 202,280 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ARWR shares. Citigroup lowered their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 27th. Piper Sandler reduced their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. Finally, Sanford C. Bernstein dropped their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Hold” and an average price target of $43.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.